Figure 3 | Signal Transduction and Targeted Therapy

Figure 3

From: The molecular determinants governing the immunogenicity of Japanese encephalitis live attenuated vaccines

Figure 3

Amino-acid mutations of each new JEV strains. Compared with SA14-14-2, SA14-9-7 and SA14-5-3 had also stable attenuated neurovirulence but poor immunogenicity in human clinical trials. In order to study the mechanism of the different immunogenicity of SA14-14-2, the critical amino acids in E protein of SA14-14-2 have been mutated to counterparts of SA14-9-7 and SA14-5-3 both singly (E-177, E-264, E-279 and E-315) and in combination (E-177/264, E-279/315 and E-177/264/279/315). These mutant viruses named as rJEV(E-177), rJEV(E-264), rJEV(E-279), rJEV(E-315), rJEV(E-177/264), rJEV(E-279/315) and rJEV(E-177/264/279/315) were generated and then the immunogenicity of mutants investigated.

Back to article page